Note: Descriptions are shown in the official language in which they were submitted.
CA 02814952 2014-11-13
1
Brimonidine Gel Compositions and Methods of Use
[0001]
BACKGROUND OF THE INVENTION
[0002] Parabens are esters of para-hydroxybenzoic acid. They are used
primarily for
their bactericidal and fungicidal properties. Examples of parabens include
methylparaben,
ethylparaben, propylparaben, butyl paraben, isobutylparaben, isopropylparaben,
benzylparaben and their salts. Because of their low costs, long history of
safe use and the
inefficacy of natural alternatives, parabens are widely used as preservatives
in the cosmetic
and pharmaceutical industries. See Darbre et al., 24 J. Appl. Toxicol. 5-13
(2004) and
references therein.
[0003] Carbomer is a generic name of Carbopol , a trademarked product
from
Lubrizol. Carbomer and Carbopol are used interchangeably in the present
application,
referring to a synthetic polymer of acrylic acid cross-linked with polyalkenyl
ethers or
divinyl glycol. It can be a homopolymer of acrylic acid, cross-linked with an
allyl ether
pentaerythritol, ally' ether of sucrose, or allyl ether of propylene.
Carbomers have been
used as vehicles for drug delivery. They have a long history of safe and
effective use in
topical gels, creams, lotions, and ointments, as supported by extensive
toxicology studies.
They have been shown to have extremely low irritancy properties and are non-
sensitizing
with repeat usage. Carbomers or carbomer copolymers have been used in topical
formulations, e.g., for thickening, emulsifying or suspending.
[0004] Brimonidine is a selective alpha-2-adrenergic agonist. It has
been used as
either monotherapy or as adjunctive therapy to lower intraocular pressure
(TOP) in the
treatment of glaucoma and ocular hypertension (OHT) since its approval in
1996.
Brimonidine has also been found to be useful in treating various skin
disorders, such as
rosacea, erythema caused by rosacea, see, e.g., U.S. Ser. No. 10/853,585 to
DeJovin et al.;
U.S. Ser. No. 10/626,037 to Scherer; U.S. Ser. No. 12/193,098 to Theobald et
al.;
telangiectasias, see, e.g., U.S. Patent Application Publication No.
2006/0264515. Topical
gel compositions comprising brimonidine, carbomer and paraben(s) for the
treatment of
skin disorders have been described, see for example, U.S. Ser. No. 10/853,585
to DeJovin
et al.; U.S. Ser. No. 12/193,098 to Theobald et at., etc.
CA 02814952 2013-04-17
WO 2012/052479
PCT/EP2011/068263
2
[0005] In the present invention, crystalline particles of methylparaben
have been
unexpectedly observed in some brimonidine topical gel formulations and placebo
formulations containing carbomer and methylparaben.
[0006] There is a need for a topical gel composition containing carbomer
and
methylparaben that is substantially free of paraben crystalline particles and
meets the
antimicrobial requirement over an extended period of storage. Such
compositions and
related methods and products are described in the present application.
BRIEF SUMMARY OF THE INVENTION
[0007] In one general aspect, embodiments of the present invention
relate to a topical
gel composition comprising:
0.05 to 0.20% (w/w) methylparaben;
one or more second preservatives;
0.80 to 1.50% (w/w) carbomer; and
9.0 to 13.0% (w/w) total polyol;
wherein the topical gel composition has a pH of 4.5 to 7.5; and
wherein when the concentration of methylparaben is greater than 0.15%
(w/w), the concentration of carbomer is less than 1.25% (w/w).
[0008] In another general aspect, embodiments of the present invention
relate to a
topical gel composition comprising:
0.01 to 5% (w/w) brimonidine;
0.05 to 0.20% (w/w) methylparaben;
one or more second preservatives;
0.80 to 1.50% (w/w) carbomer; and
9.0 to 13.0% (w/w) total polyol;
wherein the topical gel composition has a pH of 4.5 to 7.5; and
wherein when the concentration of methylparaben is greater than 0.15%
(w/w), the concentration of carbomer is less than 1.25% (w/w).
[0009] Another general aspect of the present invention relates to a
topical gel
composition comprising:
0.1 to 0.6% (w/w) brimonidine tartrate;
0.05 to 0.15% (w/w) methylparaben;
CA 02814952 2014-11-13
=
=
3
one or more second preservatives selected from the group consisting of
sodium benzoate, phenoxyethanol, benzyl alcohol, imidazolidinyl urea, and
diazolidinyl
urea;
0.80 to 1. 50% (w/w) carbomer ;
4.5 to 6.5% (w/w) propylene glycol;
4.5 to 6.5% (w/w) glycerol; and
purified water;
wherein the pH of the topical gel composition is adjusted to a pH of 5.0 to
6.5 by an adequate amount of sodium hydroxide aqueous solution.
[0010] In another general aspect, embodiments of the present invention
relate to a
method of treating or preventing a skin disorder in a subject. The method
comprises
topically administering to a skin area of the subject a topical gel
composition according to
an embodiment of the present invention, wherein the skin area is, or is prone
to be, affected
by the skin disorder.
[0011] Other aspects, features and advantages of the invention will be
apparent from
the following disclosure, including the detailed description of the invention
and its
preferred embodiments and the appended claims.
DETAILED DESCRIPTION OF THE INVENTION
[0012] Various publications, articles and patents are cited or described
in the
background and throughout the specification. Discussion of documents, acts,
materials, devices,
articles, or the like which have been included in the present specification is
for the purpose
of providing context for the present invention. Such discussion is not an
admission that
any or all of these matters form part of the prior art with respect to any
inventions
disclosed or claimed.
[0013] Unless defined otherwise, all technical and scientific terms used
herein have the
same meaning as commonly understood to one of ordinary skill in the art to
which this
invention pertains. Otherwise, certain terms used herein have the meanings as
set forth in
the specification. It must be noted that as used herein and in the appended
claims, the
singular foul's "a," "an," and "the" include plural references unless the
context clearly
dictates otherwise.
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
4
100141 As used herein, "erythema or a symptom associated therewith" is
intended to
encompass any type or classification of redness of skin caused by hyperemia or
congestion
of the capillaries in the lower layers of the skin, and any symptom associated
therewith.
The term "erythema or a symptom associated therewith" encompasses skin redness
or rash
resulting from any causes. For example, it can be caused by skin injury,
surgery and other
procedures on the skin, infection, inflammation, emotion, exercise, heat
(erythema ab igne),
cold, photosensitivity, radiation therapy, allergy, hot flush diseases,
medications, etc.
Examples of "erythema or a symptom associated therewith" include, but are not
limited to,
photosensitivity, erythema multiforme, and erythema nodusum, and their
associated
symptoms. Photosensitivity is caused by a reaction to sunlight, which often
occurs when
some factors, such as an infection or a medication, increase the sensitivity
to ultraviolet
radiation. However, photosensitivity can also occur without any increased
sensitivity to
ultraviolet radiation. Erythema multiforme is characterized by raised spots or
other lesions
on the skin, which are usually caused by a reaction to medications,
infections, or illness.
Most erythema multiforme is associated with herpes simplex or mycoplasma
infections.
Erythema nodosum is a form of erythema that is accompanied by tender lumps,
usually on
the legs below the knees, and may be caused by certain medications or
diseases.
[0015] In one particular embodiment of the present invention, the term
"erythema or a
symptom associated therewith" includes erythema of rosacea, i.e., erythema or
a symptom
associated therewith in a patient with rosacea. Rosacea is an inflammatory
skin disorder
that generally affects the cheeks, nose, chin, and forehead of a patient. The
major symptom
of rosacea is erythema, i.e., the abnormal redness of the skin.
[0016] The term "erythema or a symptom associated therewith" encompasses
different
degrees or grades of erythema or a symptom associated therewith, from mild to
severe.
[0017] In view of the present disclosure, a skin area that is affected by
erythema or that
is prone to be affected by erythema can be identified using any diagnostic
signs or means
known in the art, and can be treated by methods according to embodiments of
the present
invention.
[0018] As used herein, "telangiectasia or a symptom associated
therewith" refers to a
visible, permanent abnormal dilation of blood vessels, such as arterioles and
venules. A
visible blood vessel is a blood vessel visually discernable as a line to an
observer without
the aid of magnifying equipment (other than spectacles normally used by the
observer). In
various aspects, a telangiectatic blood vessel can have a diameter of at least
about 0.5 mm.
Telangiectasias can be associated with numerous conditions, syndromes,
diseases, and
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
disorders. For example, a facial telangiectasia can be associated with age,
sun exposure,
and alcohol use. Other diseases, disorders, conditions, and syndromes
associated with
telangiectasias include, in non-limiting example, scleroderma, hereditary
hemorrhagic
telangiectasia (Olser-Rendu syndrome), ataxia-telangiectasia, spider angioma,
cutis
5 marmorata telangiectasia congenita, Bloom syndrome, Klippel-Trenaunay-
Weber
syndrome, Sturge-Weber disease, xeroderma pigmentosa, nevus flammeus,
generalized
essential telangiectasias (GET), angioma serpiginosum, spider naevi, CREST
syndrome,
basal cell carcinoma, and unilateral nevoid telangiectasia.
[0019] In one particular embodiment of the present invention, the term
"telangiectasia
or a symptom associated therewith" includes telangiectasia associated with
rosacea, i.e.,
telangiectasia or a symptom associated therewith in a patient with rosacea.
[0020] In another particular embodiment of the present invention, the
term
"telangiectasia or a symptom associated therewith" includes sun-
induced/photodamage
telangiectasia.
[0021] The term "telangiectasia or a symptom associated therewith"
encompasses
different degrees or grades of telangiectasia or symptoms associated
therewith, from mild
to severe.
[0022] In view of the present disclosure, a skin area that is affected
by telangiectasia or
that is prone to be affected by telangiectasia can be identified using any
diagnostic signs or
means known in the art, and can be treated by methods according to embodiments
of the
present invention.
[0023] As used herein, the term "brimonidine" refers to the compound (5-
bromo-
quinoxalin-6-y1)-(4,5-dihydro-1H- imidazol-2-y1)-amine having the structure of
Formula
(I):
Br
NH 10 I
Formula (I)
and any pharmaceutically acceptable salt of the compound, such as brimonidine
tartrate.
[0024] The phrase "pharmaceutically acceptable salt(s)," as used herein,
means those
salts of a compound of interest that are safe and effective for topical use in
mammals and
that possess the desired biological activity. Pharmaceutically acceptable
salts include salts
CA 02814952 2014-11-13
-
6
of acidic or basic groups present in the specified compounds. Pharmaceutically
acceptable
acid addition salts include, but are not limited to, hydrochloride,
hydrobromide,
hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate,
isonicotinate, acetate,
lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate,
succinate, maleate,
gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate,
glutamate,
methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and
pamoate (i.e.,
1,11-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Certain compounds used in
the present
invention can form pharmaceutically acceptable salts with various amino acids.
Suitable
base salts include, but are not limited to, aluminum, calcium, lithium,
magnesium,
potassium, sodium, zinc, and diethanolamine salts. For a review on
pharmaceutically
acceptable salts see Berge et al., 661 Pharm. Sci. 1-19 (1977).
[0025] As used herein, the term "hydrate" means a compound of
interest, or a
pharmaceutically acceptable salt thereof, that further includes a
stoichiometric or non-
stoichiometric amount of water bound to it by non-covalent intermolecular
forces.
[0026] The term "topical gel composition" or "topical gel
formulation," as used herein,
means any gel formulation or composition which is pharmaceutically and/or
cosmetically
acceptable for topical delivery of the specified compound(s) according to
embodiments of
the invention.
[0027] As used herein, the term "composition" is intended to encompass a
product
comprising the specified ingredient in the specified amount, as well as any
product which
results, directly or indirectly, from combinations of the specified ingredient
in the specified
amount.
[0028] As used herein, the term "subject" means any animal,
preferably a mammal,
most preferably a human, to whom will be or has been administered compounds or
topical
formulations according to embodiments of the invention. The term "mammal" as
used
herein, encompasses any mammal. Examples of mammals include, but are not
limited to,
cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs,
monkeys, humans,
etc., more preferably a human. Preferably, a subject is in need of, or has
been the object of
observation or experiment of, treatment or prevention of a skin disorder, such
as rosacea,
erythema of rosacea, telangiectasia, psoriasis, purpura, erythema of acne,
eczema, non-
rosacea-related inflammation of the skin, flushing, skin sagging, creasing
and/or wrinkling,
or a symptom associated therewith.
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
7
[0029] In one embodiment, "treatment" or "treating" refers to an
amelioration,
prophylaxis, or reversal of a disease or disorder, or of at least one
discernible symptom
thereof In another embodiment, "treatment" or "treating" refers to an
amelioration,
prophylaxis, or reversal of at least one measurable physical parameter related
to the disease
or disorder being treated, not necessarily discernible in or by the mammal. In
yet another
embodiment, "treatment" or "treating" refers to inhibiting or slowing the
progression of a
disease or disorder, either physically, e.g., stabilization of a discernible
symptom,
physiologically, e.g., stabilization of a physical parameter, or both. In yet
another
embodiment, "treatment" or "treating" refers to delaying the onset of a
disease or disorder.
[0030] In certain embodiments, compounds of interest are administered as a
preventative measure. As used herein, "prevention" or "preventing" refers to a
reduction of
the risk of acquiring a given disease or disorder. In a preferred mode of the
embodiment,
the specified compounds are administered as a preventative measure to a
subject having a
predisposition to a disease or disorder even though symptoms of the disease or
disorder are
absent or minimal.
[0031] In an embodiment of the present invention, methylparaben
crystalline particles
have been observed in brimonidine topical gel formulations containing 0.2%
(w/w) or
more methylparaben, particularly in batch sizes of 300 g to 250 kg. See
Example 1 below.
This observation is surprising in view of the solubility of methylparaben.
According to a
Material Safety Data Sheet (MSDS) of methylparaben, the solubility of
methylparaben in
water is about 0.25% (w/w) at 20 C or about 0.30% (w/w) at 25 C. The
solubility of
methylparaben in propylene glycol is 1 in 5 at 25 C, the solubility of
methylparaben in
warm glycerol is about 1.4%, and see: MSDS, Chemicals & Laboratory Equipment,
Science Lab.com, World Wide Web: sciencelab.com/msds.php?msdsId=9926083.
Further,
according to Handbook of Pharmaceutical Excipients (supra), the solubility of
methylparaben in propylene glycol is 1 in 5 at 25 C,
[0032] In view of methylparaben's solubility in polyols and water, it
would have been
reasonably expected that 0.30% (w/w) or less methylparaben would remain
completely
soluble in a topical gel composition comprising about 4.5 to 6.5% (w/w) of a
first polyol in
which methylparaben is substantially soluble, about 4.5 to 6.5% (w/w) of a
second polyol,
and about 90% (w/w) or less water. The detection of methylparaben crystalline
particles in
the composition is completely unexpected. Not wishing to be bound by theory,
the
methylparaben crystalline particles observed in the brimonidine topical gel
and placebo
compositions may have been caused by one or more reasons, such as
recrystallization of
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
8
methylparaben during the manufacturing process, or recrystallization of
methylparaben
during storage resulting from excipient-excipient interaction. Without the
surprising
observation made in the present invention, one would not have reasonably
expected the
existence of methylparaben crystals in the topical gel compositions, let alone
to develop an
improved topical gel formulation free of the crystals.
[0033] Embodiments of the present invention relate to an improved
topical gel
composition that is substantially free of crystalline particles and has
microbiological
quality over an extended period of storage. The improved topical gel
composition
according to an embodiment of the present invention comprises:
0.05 to 0.20% (w/w) methylparaben;
one or more second preservatives;
0.80 to 1.50% (w/w) carbomer; and
9.0% to 13.0% (w/w) total polyol;
wherein the topical gel composition has a pH of 4.5 to 7.5; and
wherein when the concentration of methylparaben is greater than 0.15%
(w/w), the concentration of carbomer is less than 1.25% (w/w).
[0034] According to embodiments of the present invention, the amount of
methylparaben in the composition is about 0.05%, 0.075%, 0.10%, 0.125% ,
0.15%, or
0.20% (w/w).
[0035] Suitable second preservatives that can be used in embodiments of the
present
invention include any preservatives that are suitable for topical application.
Examples of
the second preservatives include, but are not limited to, sodium benzoate,
phenoxyethanol,
benzyl alcohol, imidazolidinyl urea, or diazolidinyl urea. Additional examples
of the
second preservatives may include, quaternary ammonium compounds, such as
benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride,
and
cetylpyridinium chloride; alcoholic agents, such as, chlorobutanol;
antibacterial esters,
such as esters of parahydroxybenzoic acid; and other anti-microbial agents
such as
chlorhexidine, chlorocresol, benzoic acid, polymyxin, mupirocin, erythromycin,
clindamycin, gentamicin, polymyxin, bacitracin, silver sulfadiazine, etc.
[0036] Preferably, the second preservative is effective in inactivating
challenge doses
of Gram-negative and Gram-positive microorganisms, as well as yeast.
[0037] According to embodiments of the present invention, the one or
more second
preservatives comprise phenoxyethanol and the amount of phenoxyethanol in the
composition is, or is greater than 0.3%, 0.35%, 0.4%, 0.45%, or 0.5% (w/w).
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
9
[0038] According to embodiments of the present invention, the carbomer
is a synthetic
polymer of acrylic acid cross-linked with polyalkenyl ethers or divinyl
glycol. It can be a
homopolymer of acrylic acid, cross-linked with an allyl ether pentaerythritol,
allyl ether of
sucrose, or allyl ether of propylene. Examples of carbomers that can be used
in the present
invention include, but are not limited to, carbomer 910, 934P, 940, 941, 1342,
Carbopol
974P (carbomer 974P), and Carbopol 980 (carbomer 980).
[0039] Preferably, the carbomer is carbomer 934P, carbomer 974P, or
carbomer 980.
[0040] According to embodiments of the present invention, the amount of
the
carbomer in the composition is about 0.8%, 0.85%, 0.95%, 1.05%, 1.15%, 1.25%,
1.35%,
1.45%, or 1.5% (w/w).
[0041] Polyol gel formulations with various ingredients solubilized
therein have been
used to minimize irritation when applied to the skin of a subject, while
ensuring
bioavailability of the active agent in the formulation. See Ofher III et al.,
"Gels and
Jellies," pp. 1327-1344 of Encyclopedia of Pharmaceutical Technology, vol. 3
(ed. by
Swarbrick et al., pub. by Marcel Dekker, Inc., 2002); or Pena, "Gel Dosage
Forms: Theory,
Formulation, and Processing," pp. 381-388 of Topical Drug Delivery
Formulations, (ed.
by Osborne et al., pub. by Marcel Dekker, Inc., 1990). Polyols in gel
formulations can
serve one or more functions, such as solubilizing agents, moisturizers,
emollients, skin
humectant, skin-penetration agents, etc. Suitable polyols that can be used in
embodiments
of the present invention include, but are not limited to, glycerine, propylene
glycol,
dipropylene glycol, hexylene glycol, butylene glycol, and liquid polyethylene
glycols, such
as polyethylene glycol 200 to 600, and glycerol.
[0042] According to embodiments of the present invention, the amount of
the total
polyols in the composition is about 9.0% to 13.0% (w/w), for example about
9.0%, 9.5%,
10.0%, 10.5%, 11.0%, 11.5%, 12.0%, 12.5%, or 13.0% (w/w).
[0043] In an embodiment of the present invention, the topical gel
composition
comprises at least a first polyol in which the methylparaben is substantially
soluble.
[0044] Preferably, the topical gel composition comprises the first
polyol and a second
polyol, such as propylene glycol and glycerine, respectively.
[0045] According to embodiments of the present invention, the amount of
each of the
first and second polyols in the composition is independently about 4.5% to
6.5% (w/w), for
example 4.5%, 5.0%, 5.5%, 6.0%, or 6.5% (w/w).
[0046] In a preferred embodiment, a topical gel composition according to
embodiments of the invention further comprises a water dispersible form of
titanium
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
dioxide (Ti02), preferably at an amount that is sufficient to mask the color
of brimonidine
or another colored ingredient in the formulation, but would not cause
irritation to the skin.
TiO2 may cause mild irritation and reddening to the eyes, thus eye contact
with the Ti02-
containing topically administrable composition should be avoided. Titanium
dioxide
5 imparts a whiteness to the topically administrable composition and helps
to increase the
opacity and reduce the transparency of the composition. Titanium dioxide
absorbs, reflects,
or scatters light (including ultraviolet radiation in light), which can help
protect products
from deterioration. Titanium dioxide can also be used as a sunscreen to
protect the user
from the harmful effects of ultraviolet radiation that is part of sunlight.
10 [0047] According to embodiments of the present invention, the
amount of water
dispersible form of titanium dioxide in the composition is about 0.04%,
0.0425%, 0.0525%,
0.0625%, 0.0725%, or 0.08% (w/w).
[0048] In another general aspect, a topical gel formulation according to
an embodiment
of the present invention further comprises an active pharmaceutical
ingredient, such as an
alpha adrenergic receptor agonist or a pharmaceutically acceptable salt
thereof, that is
effective to prevent or treat a skin disorder.
[0049] Alpha adrenergic receptor agonists are well known in the art. In
a preferred
embodiment, the alpha adrenergic receptor agonist may be an alpha-1 or alpha-2
adrenergic receptor agonist. The alpha adrenergic receptor agonists included
in the
invention may or may not show selectivity for either the alpha-1 or alpha-2
adrenergic
receptors. For example, some may be considered as being both alpha-1 and alpha-
2
adrenergic receptor agonists. More preferably, the alpha adrenergic receptor
agonist may
be a selective alpha-1 or a selective alpha-2 adrenergic receptor agonist.
[0050] Examples of selective alpha-1 adrenergic receptor agonists
include
oxymetazoline, phenylephrine, and methoxyamine. Examples of selective alpha-2
adrenergic receptor agonists include brimonidine, tetrahydrozoline,
naphazoline,
xylometazoline, epinephrine, and norepinephrine.
[0051] In an embodiment of the present invention, the active
pharmaceutical ingredient
comprises 0.01 to 5% (w/w) brimonidine. The active pharmaceutical ingredient
can
optionally include one or more pharmaceutically active ingredients in addition
to
brimonidine, including, but not limited to, medications used to treat the skin
disorder or the
underlying disease that causes the skin disorder, antihistamines to control
itching,
antibiotics, corticosteroids, intravenous immunoglobulins, acetaminophen, etc.
[0052] In a preferred embodiment, the brimonidine is brimonidine
tartrate.
CA 02814952 2014-11-13
- =
11
[0053] According to embodiments of the present invention, the amount
of brimonidine
in the topical gel composition is about 0.05% to 0.1%, 0.1% to 0.4%, 0.4% to
0.7%, 0.7%
to 1%, 1% to 2%, 2% to 3%, 3% to 4%, or 4% to 5% (w/w). Preferably, the amount
of
brimonidine tartrate in the composition is about 0.1 to 0.6% (w/w).
[0054] In a preferred embodiment of the present invention, a topical gel
composition
comprises:
0.1 to 0.6% (w/w) brimonidine tartrate;
0.05 to 0.15% (w/w) methylparaben;
one or more second preservatives selected from the group consisting of
sodium benzoate, phenoxyethanol, benzyl alcohol, imidazolidinyl urea, and
diazolidinyl
urea;
0.80 to 1.50% (w/w) carbomer;
4.5 to 6.5% (w/w) propylene glycol;
4.5 to 6.5% (w/w) glycerol; and
purified water;
wherein the pH of the topical gel composition is adjusted to 5.0 to 6.5 by an
adequate amount of sodium hydroxide aqueous solution.
[0055] According to an embodiment of the present invention, the
topical gel
composition comprises greater than 0.3% (w/w) phenoxyethanol as the second
preservative
when 0.15% (w/w) or less methylparaben is used in the formulation.
[0056] A topical gel composition according to embodiments of the
present invention
can comprise additional pharmaceutically acceptable excipients, such as those
listed in
Remington: The Science and Practice of Pharmacy, 866-885 (Alfonso R. Gennaro
ed.,
19th ed., 1995); Ghosh, T. K. et al., Transdermal and Topical Drug Delivery
Systems
(1997). Examples of the additional excipients
include, but are not limited to, protectives, adsorbents, antioxidants, local
anesthetics,
buffering agents, surfactants, flavorants, fragrances, dyes, etc.
[0057] Suitable protective agents and/or cosmetic agents, and
adsorbents can include,
but are not limited to, dusting powders, zinc stearate, collodion,
dimethicone, silicones,
zinc carbonate, aloe vera gel and other aloe products, vitamin E oil,
allantoin, petrolatum,
titanium dioxide, and zinc oxide.
[0058] Suitable antioxidants can include, but are not limited to,
ascorbic acid and its
esters, sodium bisulfite, butyl ated hydroxytoluene, butylated hydroxyani
sole, tocopherols,
and chelating agents like EDTA and citric acid.
CA 02814952 2014-11-13
= ..
=
=
12
[0059] Suitable buffering agents can include, but are not limited to,
acetate buffers,
citrate buffers, phosphate buffers, lactic acid buffers, sodium buffer, and
borate buffers.
[0060] A topical gel composition according to embodiments of the
present invention
can further include local anesthetics and analgesics, such as camphor,
menthol, lidocaine,
dibucaine, and pramoxine; antifungals, such as ciclopirox, chloroxylenol,
triacetin,
sulconazole, nystatin, undecylenic acid, tolnaftate, miconazole, clotrimazole,
oxiconazole,
griseofulvin, econazole, ketoconozole, and amphotericin B.
[0061] A topical gel composition according to embodiments of the
present invention
can further include one or more antiseptics, such as iodine, povidine-iodine,
benzalkonium
chloride, benzoic acid, nitrofurazine, benzoyl peroxide, hydrogen peroxide,
hexachlorophene, phenol, resorcinol, and cetylpyridinium chloride.
[0062] The topical gel composition according to embodiments of the
present invention
can be prepared by mixing the ingredients of the composition according to
known methods
in the art, for example methods provided by standard reference texts such as:
Remington:
The Science and Practice of Pharmacy, 1577-1591, 1672-1673, 866-885 (Alfonso
R.
Gennaro ed., 19th ed., 1995); Ghosh, T. K. eta!,, Transdermal And Topical Drug
Delivery
Systems (1997).
[0063] The pH of the topical gel formulations of the invention are
preferably within a
physiologically acceptable pH range, e.g., within the range of about 4.5 to
about 7.5, more
preferably, of about 5.0 to about 6.5, such as a pH of about 5.1, 5.15, 5.2,
5.25, 5.3, 5.35,
5.4, 5.45, 5.5, 5.55, 5.6, 5.65, 5.7, 5.75, 5.8, 5.85, 5.9, 5.95, 6.1, 6.15,
6.2, 6.25, 6.3, 6.35,
6.4, 6.45, or 6.5. To stabilize the pH, preferably, an effective amount of a
buffer is
included. Acids or bases can be used to adjust the pH as needed.
[0064] In one general aspect, embodiments of the present invention
relate to a method
of treating or preventing a skin disorder, such as rosacea, erythema of
rosacea,
telangiectasia, psoriasis, purpura, erythema of acne, eczema, non-rosacea-
related
inflammation of the skin, flushing, skin sagging, creasing and/or wrinkling,
or a symptom
associated therewith, in a subject by topically administering to a skin area
of the subject a
topical gel composition according to an embodiment of the present invention,
wherein the
skin area is, or is prone to be, affected by the skin disorder. The relevant
disclosures, e.g.,
on using brimonidine to treat the one or more of skin disorders, in U.S. Ser.
No.
10/853,585 to DeJovin et al.; U.S. Ser. No. 10/626,037 to Scherer; U.S. Ser.
No.
10/607,439 to Gil et al.; U.S. Ser. No. 10/763,807 to Shanler et al.; U.S.
Ser. No.
12/193,098 to Theobald etal.; U.S. Patent Application Publication No.
2006/0264515 to
CA 02814952 2014-11-13
= ..
13
DeJovin et al.; U.S. Ser. No. 12/621,942 to DeJovin et al.; U.S. Patent
Application
Publication No. 2005/0020600 to Scherer; and U.S. Patent Application
Publication No.
2009/0130027 to Shanler et al.
[0065] In an embodiment of the present invention, the topically
administrable
composition comprises about 0.1% to 0,6% (w/w), such as about 0.1%, about
0.15%, about
0.18%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about
0.45%,
about 0.5%, about 0.55%, or about 0.6% by weight of brimonidine tartrate.
[0066] To treat or prevent a skin disorder, in view of the present
disclosure, the topical
gel compositions of the invention can be topically applied directly to the
affected area in
any conventional manner known in the art, e.g. by dropper, applicator stick,
or cotton swab,
as a mist via an aerosol applicator, via an intradermal or transdermal patch,
or by simply
spreading a formulation of the invention onto the affected area with fingers,
a sponge, a
pad, or wipes. Generally, the amount of a topical formulation of the invention
applied to
the affected skin area ranges from about 0.0001 g/cm2 of skin surface area to
about 0.05
g/cm2, preferably 0.002 g/cm2 to about 0.005 g/cm2 of skin surface area.
Typically, one to
four applications per day are recommended during the term of treatment.
[0067] Methods of the present invention can be used in conjunction
with one or more
other treatments and medications for the skin disorder, such as the
medications used to
treat the underlying disease that causes the skin disorder, antihistamines to
control itching,
antibiotics, corticosteroids, intravenous immunoglobulins, acetaminophen, etc.
[0068] The other medicament or treatment can be administered to the
subject
simultaneously with, or in a sequence and within a time interval of, the
administration of
brimonidine, such that the active ingredients or agents can act together to
treat or prevent
the skin disorder. For example, the other medicament or treatment and
brimonidine can be
administered in the same or separate formulations at the same or different
times.
[0069] Any suitable route of administration can be employed to deliver
the additional
treatment or medication including, but not limited to, oral, intraoral,
rectal, parenteral,
topical, epicutaneous, transdermal, subcutaneous, intramuscular, intranasal,
sublingual,
buccal, intradural, intraocular, intrarespiratory, or nasal inhalation.
[0070] This invention will be better understood by reference to the
non-limiting
examples that follow, but those skilled in the art will readily appreciate
that the examples
are only illustrative of the invention as described more fully in the claims
which follow
thereafter.
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
14
Example 1
Observation of Methylparaben Crystalline Particles in Topical Gel Compositions
[0071] Crystalline particles were first observed visually in a sampling
of 7 tubes of a
batch of brimonidine topical gel composition. These particles were isolated.
The identity
of the particles was analyzed by several analytical methods, such as HPLC test
for
identification by comparison of the retention time against standards,
differential scanning
calorimetry (DSC) for determination of melting point, NMR for a structural
identification
(by 1H and 13C), mass/ mass with UV detector and QTOF to separate and identify
the
different masses, etc. Based on these analyses, it has been concluded that the
observed
crystals are crystals of methylparaben (hereinafter abbreviated as POBM or
MPOB), which
is a preservative used in the composition. According to the process used for
manufacturing
the batch, methylparaben was first dissolved in propylene glycol at 50 C (122-
140 F) in
the preservative phase.
[0072] Microscopic observations were performed on additional
representative batches
of brimonidine topical gel compositions and placebo gel compositions
containing 1.25%
(w/w) carbomer, POBM and other ingredients. The observations have been done on
one tube
of each batch, with the microscope Axiolab DRBKT Zeiss no. 023733.01 with a
camera ICC Zeiss
or the microscope Olympus BX60. The microscopic observations were done at 5 C
and room
temperature.
[0073] As shown in Table 1, methylparaben crystalline particles were
unpredictably
observed in both brimonidine and placebo gel compositions containing 0.2% or
0.3% by
weight methylparaben (POBM).
[0074] Table 1: Results of microscopic observations of representative
batches of gel
composition
Date ofMicroscopic Batch Size No. Tubes Date of
Composition
Manufacturing Observation
Observed Observation
April 2008 Placebo, 0.3% POBM Crystals 130 kg
7 Dec. 2008
April 2008 Placebo, 0.3% POBM No crystal 130
kg 5 Dec. 2008
July 1, 2009 Placebo, 0.3% POBM Crystals 300 g ¨ 2
kg 1 Oct. 2009
August 25, 2009 Placebo, 0.3% POBM Crystals 300 g ¨ 2 kg 1
Oct. 2009
0.03% Brimonidine 200 ¨ 250 kg
Sept. 2, 2009 0.3% POBM No crystal 1 Feb.
2010
0.06% Brimonidine 200 ¨ 250 kg
Sept. 7, 2009 0.3% POBM Crystals 1 Feb.
2010
0.07% Brimonidine 200 ¨ 250 kg
July 6, 2009 0.3% POBM Crystals 1 Feb.
2010
0.18% Brimonidine 300 g ¨2 kg
Sept 15, 2009 0.3% POBM Crystals 1 Oct.
2009
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
0.5% Brimonidine 200 ¨ 250 kg
July 16, 2009 0.3% POBM Crystals 1
Feb. 2010
1% Brimonidine 1% 200 ¨ 250 kg
Sept. 18, 2009 0.3% POBM No crystal 1
Feb. 2010
2% Brimonidine 2% 200 ¨ 250 kg
Sept. 29, 2009 0.3% POBM No crystal 1
Feb. 2010
0.06% Brimonidine 300 g ¨ 2 kg
Sept. 10, 2009 0.3% POBM Crystals 1
Oct. 2009
1% Brimonidine 300 g ¨2 kg
Sept. 17, 2009 0.3% POBM No crystal 1
Oct. 2009
Jan. 12, 2010 Placebo, 0.2% POBM Crystals 300 g 1
Feb. 4, 2010
0.18% Brimonidine 800g
Feb. 10,
Dec. 22, 2009 0.2% POBM No crystal 1
2010
[0075] Assays
were conducted to estimate the concentration of methylparaben
solubilized in a batch originally containing 0.3% (w/w) of methylparaben, in
which
crystalline particles were observed. Centrifugation was performed on the batch
to collect
5 crystals at the bottom of the centrifuge tube, thus removing them from
the supernatant.
The methylparaben concentration in the supernatant was measured and found to
be about
0.2% (w/w), which was about 66% of the 0.3% (w/w) in the original formulation.
The
reduction in the concentration of soluble methylparaben in the composition
raises non-
conformity issues and may result in poor microbiological quality of the
composition over
10 an extended period of storage.
[0076] The presence of methylparaben crystalline particles in the
topical gel
formulations is surprising in view of the solubility of methylparaben. In
order to find a
solution to avoid the crystallization problem, several hypotheses have been
postulated and
evaluated to uncover the potential cause and possible solution of the problem.
15 Example 2
Improved Topical Gel Compositions Free of Methylparaben Crystalline Particles
[0077] Various changes to the formulation and the process of
manufacturing the
formulation have been made in order to obtain improved topical gel
formulations that are
free of the observed paraben crystals and have acceptable microbiological
quality. For
example, methylparaben, also named methyl parahydroxybenzoate (POBM), was
replaced
with the more water soluble Na POBM, but crystalline particles of Na POBM were
still
observed at 0.3% (w/w) Na POBM. Addition of 0.1% of EDTA into the formulation
resulted in immediate recrystallization of the POBM at 0.3% (w/w) in the
formulation,
suggesting that the 0.3% (w/w) concentration of POBM may be too high.
CA 02814952 2013-04-17
WO 2012/052479 PCT/EP2011/068263
16
[0078] Numerous formulations with different ingredients and varying
concentrations of
the ingredients were made and tested for the presence of the paraben crystals
by
microscopic observations. The microbiological quality of the formulations was
also
analyzed by using acceptance-test criteria in preservative-efficacy testing
(PET) in the
United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).
[0079] Based on microscopic observations and PET analyses, it was found
that
improved topical gel compositions containing 0.05% to 0.20% (w/w)
methylparaben; one
or more second preservatives, such as 0.3% (w/w) or more phenoxyethanol; 0.80
to 1.50%
(w/w) carbomer, such as Carbopol 974P NF; 9.0% to 13.0% (w/w) total polyol,
such as
4.5 to 6.5% (w/w) of a first polyol, e.g., propylene glycol, 4.5 to 6.5% (w/w)
of a second
polyol, e.g., glycerol; and one or more other ingredients, such as purified
water, titanium
dioxide, optionally an effective amount of brimonidine tartrate, with a pH of
5.0 to 6.5
adjusted by an adequate amount of sodium hydroxide, were free of methylparaben
crystals
after an extended period of storage and passed criteria of EP and USP. See
Table 2, in
which the concentration of carbomer in each of the formulations was 1.25%
(w/w).
[0080] Table 2: Results of microscopic observations and PET of topical
gel
formulations
Batch Preservative Period of Microscopic PET Result
Size (kg) Concentration (w/w) Storage Observation
(weeks)
2 0.1% MPOB 21 No crystal Failed criteria
A of
0.3% Phenoxyethanol EP at 48 hours
200 0.1% MPOB 24 No crystal Passed EP and
0.4% Phenoxyethanol USP
2 0.125% MPOB 12 No crystal Passed EP and
0.4% Phenoxyethanol USP
200 0.125% MPOB 7 No crystal Passed EP and
0.4% Phenoxyethanol USP
[0081] It was further discovered that when the amount of methylparaben
was more
than 0.15% (w/w), decreasing the amount of carbomer reduced the formation of
methylparaben crystals. See, for example, Table 3.
[0082] Table 3: Results of microscopic observation of gel compositions
CA 02814952 2014-11-13
=
17
Batch Composition Microscopic
Size Observation
300G POBM : 0,2 Crystals after one
Phenoxyethanol : 0.3 month storage at RT
Carbopol 980: 1.25
300G POBM : 0.2 No crystal observed
Phenoxyethanol : 0.3 after one month
Carbopol 980 : 0.8 storage at RT
[0083] It will be appreciated by those skilled in the art that changes
could be made to
the embodiments described above without departing from the broad inventive
concept
thereof The scope of the claims should not be limited by the preferred
embodiments
and examples, but should be given the broadest interpretation consistent with
the
description as a whole.
